Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 18

1.

Use of drug-eluting stents as a function of predicted benefit: clinical and economic implications of current practice.

Amin AP, Spertus JA, Cohen DJ, Chhatriwalla A, Kennedy KF, Vilain K, Salisbury AC, Venkitachalam L, Lai SM, Mauri L, Normand SL, Rumsfeld JS, Messenger JC, Yeh RW.

Arch Intern Med. 2012 Aug 13;172(15):1145-52. doi: 10.1001/archinternmed.2012.3093.

PMID:
22777536
2.

Stent choice in primary percutaneous coronary intervention: drug-eluting stents or bare metal stents?

Valgimigli M, Airoldi F, Zimarino M.

J Cardiovasc Med (Hagerstown). 2009 Oct;10 Suppl 1:S17-26. doi: 10.2459/01.JCM.0000362040.25767.f5. Review.

PMID:
19851216
3.

The costs and quality-of-life outcomes of drug-eluting coronary stents: a systematic review.

Groeneveld PW, Suh JJ, Matta MA.

J Interv Cardiol. 2007 Feb;20(1):1-9. Review.

PMID:
17300390
4.

Comparison of drug-eluting stents with bare metal stents in patients with ST-segment elevation myocardial infarction.

Kalesan B, Pilgrim T, Heinimann K, Räber L, Stefanini GG, Valgimigli M, da Costa BR, Mach F, Lüscher TF, Meier B, Windecker S, Jüni P.

Eur Heart J. 2012 Apr;33(8):977-87. doi: 10.1093/eurheartj/ehs036. Epub 2012 Feb 23. Review.

PMID:
22362513
5.

Coronary artery stents: a rapid systematic review and economic evaluation.

Hill R, Bagust A, Bakhai A, Dickson R, Dündar Y, Haycox A, Mujica Mota R, Reaney A, Roberts D, Williamson P, Walley T.

Health Technol Assess. 2004 Sep;8(35):iii-iv, 1-242. Review.

6.

Drug-eluting stents: a systematic review and economic evaluation.

Hill RA, Boland A, Dickson R, Dündar Y, Haycox A, McLeod C, Mujica Mota R, Walley T, Bagust A.

Health Technol Assess. 2007 Nov;11(46):iii, xi-221. Review.

7.

Recent progress in percutaneous coronary intervention: evolution of the drug-eluting stents, focus on the XIENCE V drug-eluting stent.

Doostzadeh J, Clark LN, Bezenek S, Pierson W, Sood PR, Sudhir K.

Coron Artery Dis. 2010 Jan;21(1):46-56. doi: 10.1097/MCA.0b013e328333f550. Review.

PMID:
19952925
8.

Management of drug-eluting stent restenosis.

Ishikawa K, Aoyama Y, Hirayama H.

J Invasive Cardiol. 2012 Apr;24(4):178-82. Review.

9.

Drug-eluting stents vs. intracoronary brachytherapy for in-stent restenosis: a meta-analysis.

Lu YG, Chen YM, Li L, Zhao RZ, Fu CH, Yan H.

Clin Cardiol. 2011 Jun;34(6):344-51. doi: 10.1002/clc.20900. Epub 2011 Apr 27. Review.

10.

Stent thrombosis and drug-eluting stents.

Takayama T, Hiro T, Hirayama A.

J Cardiol. 2011 Sep;58(2):92-8. doi: 10.1016/j.jjcc.2011.07.003. Epub 2011 Aug 11. Review.

11.

Another view of personalized medicine: optimizing stent selection on the basis of predicted benefit in percutaneous coronary intervention.

Wimmer NJ, Yeh RW.

Trends Cardiovasc Med. 2012 Jan;22(1):23-8. doi: 10.1016/j.tcm.2012.06.006. Epub 2012 Jul 28. Review.

12.

Coronary stent selection and optimal course of dual antiplatelet therapy in patients at high bleeding or thrombotic risk: navigating between limited evidence and clinical concerns.

Ariotti S, Costa F, Valgimigli M.

Curr Opin Cardiol. 2015 Jul;30(4):325-32. doi: 10.1097/HCO.0000000000000185. Review.

PMID:
26049377
13.

Percutaneous coronary intervention with second-generation drug-eluting stent versus bare-metal stent: Systematic review and cost-benefit analysis.

Poder TG, Erraji J, Coulibaly LP, Koffi K.

PLoS One. 2017 May 12;12(5):e0177476. doi: 10.1371/journal.pone.0177476. eCollection 2017. Review.

14.

Dexamethasone-eluting vascular stents.

Hämäläinen M, Nieminen R, Uurto I, Salenius JP, Kellomäki M, Mikkonen J, Kotsar A, Isotalo T, Teuvo Tammela LJ, Talja M, Moilanen E.

Basic Clin Pharmacol Toxicol. 2013 May;112(5):296-301. doi: 10.1111/bcpt.12056. Epub 2013 Mar 9. Review.

15.
16.

Dual Antiplatelet Therapy in Patients with Glucose-6-Phosphate Dehydrogenase Deficiency undergoing PCI with Drug-Eluting Stents.

Biscaglia S, Ferri A, Pavasini R, Campo G, Ferrari R.

J Atheroscler Thromb. 2015;22(5):535-41. doi: 10.5551/jat.29371. Epub 2015 Apr 3. Review.

17.

Optimal duration of dual antiplatelet therapy after coronary stent implantation.

Witberg G, Lev E, Kornowski R.

Am J Cardiol. 2015 Nov 15;116(10):1631-6. doi: 10.1016/j.amjcard.2015.08.029. Epub 2015 Sep 3. Review.

PMID:
26456206
18.

[Antiplatelet therapy: should it be withdrawn before any invasive procedure?].

Maeyns K, Legrand V, Piérard LA, Lancellotti P.

Rev Med Liege. 2008 Mar;63(3):136-40. Review. French.

PMID:
18561769

Supplemental Content

Support Center